diabetics

Takeda Filed for US Approval of Diabetes Drug Alogliptin

Filed in archive News , Treatment on January 4, 2008

The Japanese pharmaceutical company - Takeda - announced that it is seeking U.S. approval of its diabetes Drug Alogliptin (SYR-322).

Takeda Filed for US Approval of Diabetes Drug Alogliptin


Alogliptin is a diabetes drug that Takeda hopes to replace Actos (Pioglitazone HCl) - another Takeda diabetes drug.

[Alogliptin, or SYR-322, is in a new class of oral agents for the treatment of type 2 diabetes, called DPP-4 inhibitor, regulating blood glucose levels, and the class also includes Merck & Co's Januvia and Novartis AG's Galvus]

According to Takeda spokesman Toshiyuki Ikeuchi:

"We are hoping Alogliptin to boost our diabetes franchise, which is a very important field for us."
The approval process is expected to take about a year."


Find more details from the UK Guardian.



Permalink: Takeda Filed for US Approval of Diabetes Drug Alogliptin

Tags: Actos  Alogliptin  SYR322  Takeda  Pharmaceuticals  diabetes  drug  DPP4  inhibitor  takeda  diabetes+drug 

Vote for Takeda Filed for US Approval of Diabetes Drug Alogliptin:

  • Currently 6.33/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 6.33 out of 3 vote(s) cast.
 
Share It
RSSrss
Google google
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
TwitterFollow us on Twitter!
Most Popular   Best of   Blogs, Blogging & Blogosphere   Challenges   Developments   Diabetics' Device   Did you know   Diet   Education   Exercise   Family Matters   Friends   Fun   Information   Information about   Inspiration   Interviews   Lifestyle   Misc   News   Notable